| Autor: |
Martínez-Salazar B; Department of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland., Carregaro Pereira V; Department of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland., Hauyon-La-Torre Y; Department of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland., Khamesipour A; Centre for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran 14166, Iran., Tacchini-Cottier F; Department of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland. |
| Abstrakt: |
Leishmania major ( L. major ) causes cutaneous leishmaniasis in the Old World. The infection mostly induces a localized lesion restricted to the sand fly bite. The costs and the side effects of current treatments render imperative the development of new therapies that are affordable and easy to administrate. Topical treatment would be the ideal option for the treatment of cutaneous leishmaniasis. MF29 is a 3-haloacetamidobenzoate that was shown in vitro to inhibit tubulin assembly in Leishmania . Here, we tested a topical cream formulated with MF29. BALB/c mice were infected in the ear dermis with L. major metacyclic promastigotes and once the lesion appeared, mice were treated with different concentrations of MF29 and compared to the control group treated with the cream used as the vehicle. We observed that topical application of MF29 reduced the progression of the infection while control groups developed an unhealing lesion that became necrotic. The treatment decreased the type 2 immune response. Comparison with SinaAmphoLeish, another topical treatment, revealed that MF29 treatment once a day was sufficient to control lesion development, while application SinaAmphoLeish needed applications twice daily. Collectively, our data suggest that MF-29 topical application could be a promising topical treatment for cutaneous leishmaniasis. |
